Filing Flows

Filing Flows › Lifevantage (LFVN) › Q4 2025

Lifevantage (LFVN) Q4 2025 earnings results (fourth quarter 2025)

10-Q filed Feb 4, 2026

Lifevantage (LFVN) reported revenue of $48.9M for the fourth quarter 2025 (Q4 2025), -28% from a year earlier and +3% from the quarter before. Operating margin was 1.0%, net earnings $276K (0.6% of revenue).

Revenue$48.9M
Year over year-28%
Quarter over quarter+3%
Operating margin1.0%
Net earnings$276K

Lifevantage, Q4 2025: revenue $48.9M (-28% year over year), operating margin 1.0%, net earnings $276K, operating cash flow $2.8M. The chart follows the revenue to costs, profit and cash.

Q4 2025AmountQ/QY/Y
Revenue$48.9M+3%-28%
Gross profit$36.2M-4%-34%
Operating profit$487K-79%-86%
Net earnings$276K-87%-89%
Operating cash flow$2.8M—-70%
Free cash flow$1.7M—-80%

What changed

Revenue was $48.9M in Q4 2025, down 28% year over year and up 3% from the previous quarter. Protandim® product line was the largest line at 43% of revenue. LifeVantage® product line lost $16.5M year over year (down 70%), 88% of the total change.

Gross margin was 74.0%, down 6.5 points from Q4 2024. Operating profit was $487K, a 1.0% margin (down 4.1 points year over year). Operating expenses fell 30% while revenue fell 28%. Net earnings were $276K, down 89% year over year. The effective tax rate was 41.6%.

Operating cash flow was $2.8M (down 70% year over year), 1011% of net earnings. Non-cash charges added back $752K of depreciation and amortization and $553K of share-based compensation. Working capital and other items added $1.2M. Capital expenditures of $1.1M left free cash flow of $1.7M.

Questions

What was Lifevantage's revenue in the fourth quarter 2025?

Lifevantage (LFVN) reported revenue of $48.9M for the fourth quarter 2025 (Q4 2025), -28% from a year earlier and +3% from the quarter before.

Was Lifevantage profitable in the fourth quarter 2025?

Operating profit was $487K (1.0% of revenue) and net earnings $276K.

Open the interactive Sankey →

Source: Lifevantage 10-Q on SEC EDGAR.